Jeong Hyun Yong, Lee Byong Seok, Sung Jae Kyu, Lee Tae Yong, Yoon Sae Jin, Kim Sun Joo, Chung Il Kun, Lee Suck Ho, Shin Jeong Eun, Lee Dong Soo, Baek Jong Tae, Nam Soon Woo, Yoon Sang Jeong, Kim Seok Hyun, Lee Gye Sung, Lee Jong Min, Kim An Na, Oh Jae In
Department of Internal Medicine, Chungnam National University College of Medicine, Chungnam, Korea.
Korean J Gastroenterol. 2006 Jan;47(1):15-21.
BACKGROUND/AIMS: This study was done to evaluate the efficacy of rabeprazole (proton-pump-inhibitor) and ranitidine (H(2)-receptor antagonist) in the symptom relief and treatment of erosive esophagitis diagnosed by endoscopy.
A total of 110 patients with typical gastroesophageal reflux disease (GERD) symptoms were enrolled in this multicenter study. They were randomized into rabeprazole group (53 patients) and ranitidine group (57 patients) respectively. The patients in rabeprazole group were given 10 mg of rabeprazole and ranitidine group received 300 mg of ranitidine before breakfast and dinner for 8 weeks. After the end of treatment, we evaluated the endoscopic healing rate of reflux esophagitis and symptomatic improvement.
After 8 weeks of treatment, rabeprazole group showed significantly higher complete endoscopic cure rate than ranitidine group (86.8% [46/53] vs. 57.9% [33/57], p=0.001) and higher symptomatic improvement of heartburn (91.2% [31/34] vs. 76.2% [32/42], p=0.085), especially in the first 7 days (76.7% vs. 45.3%, p=0.008). Also, rabeprazole group showed significantly higher improvement of regurgitation symptom than ranitidine group (100% [35/35] vs. 83% [39/47], p=0.009). Both group showed no differences in the improvement of chest pain and globus sensation. All the adverse events (rabeprazole group 4 events vs. ranitidine group 3 events) were mild and there was no abnormality in laboratory test.
In patients with GERD, rabeprazole 10 mg b.i.d. is superior to ranitidine 300 mg b.i.d. in healing of reflux esophagitis and resolving typical GERD symptoms. Rabeprazole is an effective and well-tolerated drug for GERD treatment.
背景/目的：本研究旨在评估雷贝拉唑（质子泵抑制剂）和雷尼替丁（H₂受体拮抗剂）缓解症状及治疗经内镜诊断的糜烂性食管炎的疗效。
本多中心研究共纳入110例有典型胃食管反流病（GERD）症状的患者。他们被分别随机分为雷贝拉唑组（53例患者）和雷尼替丁组（57例患者）。雷贝拉唑组患者在早餐和晚餐前服用10mg雷贝拉唑，雷尼替丁组患者服用300mg雷尼替丁，疗程8周。治疗结束后，评估反流性食管炎的内镜愈合率及症状改善情况。
治疗8周后，雷贝拉唑组的内镜完全治愈率显著高于雷尼替丁组（86.8%[46/53]对57.9%[33/57]，p = 0.001），烧心症状的改善程度也更高（91.2%[31/34]对76.2%[32/42]，p = 0.085），尤其是在治疗的前7天（76.7%对45.3%，p = 0.008）。此外，雷贝拉唑组反流症状的改善程度显著高于雷尼替丁组（100%[35/35]对83%[39/47]，p = 0.009）。两组在胸痛和咽部异物感的改善方面无差异。所有不良事件（雷贝拉唑组4例，雷尼替丁组3例）均较轻微，实验室检查无异常。
在GERD患者中，每日两次服用10mg雷贝拉唑在反流性食管炎愈合及缓解典型GERD症状方面优于每日两次服用300mg雷尼替丁。雷贝拉唑是一种治疗GERD有效且耐受性良好的药物。
